2026-06-14T03:53:09Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/190552025-04-24T14:34:15Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_19609col_20.500.12105_16968
Repisalud
author
Maurel, Marine
author
Howard, Jennifer
author
Kissling, Esther
author
Pozo Sanchez, Francisco
author
Pérez-Gimeno, Gloria
author
Buda, Silke
author
Sève, Noémie
author
McKenna, Adele
author
Meijer, Adam
author
Rodrigues, Ana Paula
author
Martínez-Baz, Iván
author
Mlinarić, Ivan
author
Latorre-Margalef, Neus
author
Túri, Gergő
author
Lazar, Mihaela
author
Mazagatos, Clara
author
Echeverria, Aitziber
author
Abela, Stephen
author
Bourgeois, Marc
author
Machado, Ausenda
author
Dürrwald, Ralf
author
Petrović, Goranka
author
Oroszi, Beatrix
author
Jancoriene, Ligita
author
Marin, Alexandru
author
Husa, Petr
author
Duffy, Róisín
author
Dijkstra, Frederika
author
Gallardo García, Virtudes
author
Goerlitz, Luise
author
Enouf, Vincent
author
Bennett, Charlene
author
Hooiveld, Mariëtte
author
Guiomar, Raquel
author
Trobajo-Sanmartín, Camino
author
Višekruna Vučina, Vesna
author
Samuelsson Hagey, Tove
author
Lameiras Azevedo, Ana Sofía
author
Castilla, Jesús
author
Xuereb, Gerd
author
Delaere, Bénédicte
author
Gomez, Verónica
author
Tolksdorf, Kristin
author
Bacci, Sabrina
author
Nicolay, Nathalie
author
Kaczmarek, Marlena
author
Rose, Angela Mc
author
European IVE group
funder
Unión Europea. European Centre for Disease Prevention and Control (ECDC)
2024-03-22T10:36:45Z
2024-03-22T10:36:45Z
2024-02
Euro Surveill. 2024 Feb;29(8):2400089.
10.2807/1560-7917.ES.2024.29.8.2400089
1560-7917
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
38390651
http://hdl.handle.net/20.500.12105/19055
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.
eng
Europe
Influenza
Multicentre study
Test-negative design
Vaccine effectiveness
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
research article
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
URL
https://repisalud.isciii.es/bitstreams/2e5e6036-d7fd-4d0f-9f1c-d5130b3d649e/download
File
MD5
d55ea5c4bfd30f6ee8cde72b73b68603
669685
application/pdf
Interim2023_24_Influenza_A_Vaccine_2024.pdf
URL
https://repisalud.isciii.es/bitstreams/aa52f9eb-71a0-4878-a39e-a1ef2924596e/download
File
MD5
dbbbdfa8375fd2770cc1253ac8e618c1
38756
text/plain
Interim2023_24_Influenza_A_Vaccine_2024.pdf.txt